Investing.com - Nabriva Therapeutics reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Nabriva Therapeutics announced earnings per share of $-1.11 on revenue of $2.46M. Analysts polled by Investing.com anticipated EPS of $-0.94 on revenue of $1.34M.
Nabriva Therapeutics shares are up 24.85% from the beginning of the year and are trading at $1.830 , down-from-52-week-high.They are outperforming the Nasdaq which is up 3.96% from the start of the year.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings beat by Medtronic on Tuesday, February 23, 2021, who reported EPS of $1.29 on revenue of $7.78B, compared to forecasts EPS of $1.15 on revenue of $7.77B.
AstraZeneca ADR had missed expectations on Thursday, February 11, 2021 with fourth quarter EPS of $0.535 on revenue of $7.41B, compared to forecast for EPS of $0.5504 on revenue of $7.12B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar